Exploiting cellular pathways to develop new treatment strategies for AML.

Division of Hematologic Malignancies, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center, 1650 Orleans Street, Baltimore, MD 21231, USA.
Cancer Treatment Reviews (Impact Factor: 6.02). 04/2010; 36(2):142-50. DOI: 10.1016/j.ctrv.2009.12.004
Source: PubMed

ABSTRACT The standard approaches to the treatment of acute myeloid leukemia (AML) have been predominantly based on cytarabine and anthracyclines. Yet, the outcomes associated with AML continue to be poor, especially for those patients who are older or carry higher-risk disease. In recent years, extensive research has led to the development and study of novel agents which target AML by diverse and varied mechanisms. Among these are targeted therapeutics such as kinase inhibitors and oligonucleotide constructs. These aim to suppress the production or activity of proteins, such as FLT3 and BCL2, among others, and thus disrupt related signaling cascades essential for leukemogenesis and proliferation. In addition, other agents like flavopiridol appear to target the myeloid blast by various mechanisms including suppression of cyclin-dependent kinases and interference with nucleotide synthesis. Another class of novel therapies includes inhibitors of histone deacetylase, which cause growth arrest and apoptosis through histone acetylation and resultant conformational changes. Clinical trials are now studying these and other agents alone and in combination with traditional cytotoxic therapies, with some encouraging results. In this review, we aim to provide a summary of the preclinical and clinical investigations of selected promising agents currently under study.


Available from: Amir Fathi, May 15, 2014
  • [Show abstract] [Hide abstract]
    ABSTRACT: Flavopiridol, as a cyclin-dependent kinase (CDK) inhibitor, has entered into phase II study of clinical trial in chronic lymphocytic leukemia. In our study, flavopiridol decreased cell viability, significantly arrested cell cycle in G1 phase and induced cell apoptosis in HepG2/2.2.1 cells. Flavopiridol also inhibited protein expression of cyclin D1, cyclin-dependent kinase 4 (CDK4), cyclin-dependent kinase 6 (CDK6), and downregulated X-linked IAP (XIAP) expression in a dose-dependent manner. Further studies using HepG2/2.2.1 cells transfected with CDK6 siRNA or expression vector demonstrated that CDK6 modulates expression of XIAP. Finally, treatment of HepG2/2.2.1 cells with combination of flavopiridol and embelin, as a XIAP specific inhibitor, could inhibit cell proliferation more effectively than each drug alone. Taking together, CDK6 regulates XIAP expression in hepatocellular carcinoma (HCC) cells. Combination of flavopiridol and embelin could be potentially used for HCC treatment subsequently.
    Medicinal Chemistry Research 11/2011; 21(11). DOI:10.1007/s00044-011-9867-y · 1.61 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: The CXCR4 chemokine receptor promotes survival of many different cell types. Here, we describe a previously unsuspected role for CXCR4 as a potent inducer of apoptosis in acute myeloid leukemia (AML) cell lines and a subset of clinical AML samples. We show that SDF-1, the sole ligand for CXCR4, induces the expected migration and ERK activation in the KG1a AML cell line transiently overexpressing CXCR4, but ERK activation did not lead to survival. Instead, SDF-1 treatment led via a CXCR4-dependent mechanism to apoptosis, as evidenced by increased annexin V staining, condensation of chromatin, and cleavage of both procaspase-3 and PARP. This SDF-1-induced death pathway was partially inhibited by hypoxia, which is often found in the bone marrow of AML patients. SDF-1-induced apoptosis was inhibited by dominant negative procaspase-9 but not by inhibition of caspase-8 activation, implicating the intrinsic apoptotic pathway. Further analysis showed that this pathway was activated by multiple mechanisms, including upregulation of Bak at the level of mRNA and protein, stabilization of the Bak activator Noxa, and downregulation of anti-apoptotic Bcl-XL. Furthermore, adjusting expression levels of Bak, Bcl-XL, or Noxa individually altered the level of apoptosis in AML cells, suggesting that the combined modulation of these family members by SDF-1 coordinates their interplay to produce apoptosis. Thus, rather than mediating survival, SDF-1 may be a means to induce apoptosis of CXCR4-expressing AML cells directly in the SDF-1-rich bone marrow microenvironment if the survival cues of the bone marrow are disrupted.
    Journal of Biological Chemistry 06/2013; 288(32). DOI:10.1074/jbc.M113.449926 · 4.60 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: Cancer is a consequence of mutations in genes that control cell proliferation, differentiation and cellular homeostasis. These genes are classified into two categories: oncogenes and tumor suppressor genes. Together, overexpression of oncogenes and loss of tumor suppressors are the dominant driving forces for tumorigenesis. Hence, targeting oncogenes and tumor suppressors hold tremendous therapeutic potential for cancer treatment. In the last decade, the predominant cancer drug discovery strategy has relied on a traditional reductionist approach of dissecting molecular signaling pathways and designing inhibitors for the selected oncogenic targets. Remarkable therapies have been developed using this approach; however, targeting oncogenes is only part of the picture. Our understanding of the importance of tumor suppressors in preventing tumorigenesis has also advanced significantly and provides a new therapeutic window of opportunity. Given that tumor suppressors are frequently mutated, deleted, or silenced with loss-of-function, restoring their normal functions to treat cancer holds tremendous therapeutic potential. With the rapid expansion in our knowledge on cancer over the last several decades, developing effective anticancer regimens against tumor suppressor pathways has never been more promising. In this article, we will review the concept of tumor suppression, and outline the major therapeutic strategies and challenges of targeting tumor suppressor networks for cancer therapeutics.
    Current drug targets 01/2014; 15(1). DOI:10.2174/1389450114666140106095151 · 3.93 Impact Factor